Oncology Venture – Successful US patent strategy – Irofulven Claims Accepted - English version of Swedish press release published Monday 29th May 2017
Hoersholm; May 31th, 2017 – Oncology Venture Sweden AB (OV:ST) today announced that Oncology Venture was informed by the US Patent Office that it will allow the claims in a patent application for a response predictor (DRP™) for Oncology Ventures anticancer drug Irofulven. A patent will be issued by the US Patent Office in the near future. The Orange Book allows listing of biomarker patents that are required for the screening of patients for treatment with a specific drug. After that, a generic drug cannot be filed to replace Irofulven for as long as the biomarker patent is valid."This is